Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 1
2(66.7%)
Phase 3
1(33.3%)
3Total
Phase 1(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07314385Phase 1Not Yet Recruiting

NH002-mediated Sonoporation With Chemotherapy in Advanced Pancreatic Cancer

Role: collaborator

NCT04185246Phase 1Completed

A Dose Ascending Study to Evaluate the Safety of NH002 as a Contrast Agent in Cardiac Echocardiography

Role: lead

NCT06815627Phase 3Recruiting

Safety and Efficacy Evaluation of NH002 as a Contrast Agent in Subjects Undergoing Cardiac Echocardiography

Role: lead

All 3 trials loaded